Preclinical studies have shown that gemcitabine treatment alone induces T lymphocyte expansion and tumor infiltration, increased tumor antigen cross-presentation, and significant reduction of Gr-1+CD11b+ myeloid-derived suppressor cells (MDSCs) in the spleens of tumor-bearing mice 20. The gene discussed is ITGAM; the disease is neoplasm.